(A) Fractional labeling of intracellular U-13C-glucose-derived m+3 serine from aggressive or indolent brain metastatic cells grown in Plasma, CSF, or -Ser/-Gly media.
(B) Proliferative capacity of aggressive or indolent TNBC BrM cells grown in Plasma, CSF, or -Ser/-Gly media.
(C) Fractional labeling of intracellular U-13C-glucose-derived serine from aggressive brain-trophic cell lines expressing a control shRNA (shCtrl) or PHGDH shRNA (shPHGDH #1 or shPHGDH #2)
(D) Proliferative capacity of aggressive TNBC BrM cells expressing a control shRNA (shCtrl) or PHGDH shRNA (shPHGDH #1 or shPHGDH #2).
(E) Fractional labeling of intracellular U-13C-glucose -derived serine in aggressive TNBC BrM cells with a PHGDH shRNA (shPHGDH #2) expressing either an empty vector (EV) control, catalytically active or catalytically inactive, shRNA-resistant PHGDH.
(F) Proliferative capacity of PHGDH knockdown aggressive TNBC BrM cells with a PHGDH shRNA (shPHGDH #2) expressing either an empty vector (EV) control, catalytically active or catalytically inactive, shRNA-resistant PHGDH.
Cell proliferation data was monitored over 4-6 days using an Incucyte or Multisizer Coulter Counter. Error bars represent standard deviations.